Organization Profile

You just read:

Janssen Announces Two-Drug Combination of Dolutegravir and Rilpivirine Demonstrates Efficacy in Maintaining Viral Suppression in Phase III Clinical Studies

News provided by

Janssen Sciences Ireland UC

Feb 13, 2017, 20:02 ET